Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenoldopam for Prevention of AKI in ACS
NCT01690832Phase 4Unknown
- Sponsor
- Sapienza University of Rome
- Start
- Sep 2012
- Primary completion
- Dec 2013
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of fenoldopam in contrast-induced acute kidney injury (CI-AKI) (2 arms), sponsored by Sapienza University of Rome. Primary endpoint: Incidence of contrast induced acute kidney injury at 48 hours. Status: unknown.
02
Drugs
fenoldopam
03
Conditions
contrast-induced acute kidney injury (CI-AKI)
Beyond the preview
Go deeper on NCT01690832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01690832.